Peter joined Nan Fung Life Sciences in 2017. Before joining us, Mr. Peter Bisgaard was a senior partner at Novo Ventures and has been with Novo Ventures (US) Inc. since 2009. As part of Novo’s senior team he was responsible for Novo Venture’s overall investment and portfolio strategy as well as ongoing development of Novo Ventures team in the US. Prior to that, he was with Novo A/S since 2001 in Denmark. He has investment and board experience from a large number of private and public US life sciences companies. Prior to joining Novo A/S, Peter was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. He was part of strategic and financial advisor team in multiple large Private Equity and Corporate M&A transactions and strategy projects across industry sectors.
Mr. Peter Bisgaard obtained an MSs in Engineering in 1998 from the Technical University of Denmark and was awarded a post graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.
Mr. Meng Gao is also Senior Director of the Group CEO’s Office at Nan Fung Group, a major founding investor of New Frontier. Meng is a representative of Nan Fung on the Board of New Frontier.
Prior to joining Nan Fung, Meng was a Managing Director at Blackstone’s Private Equity Group in Hong Kong. At Blackstone, he was involved in a number of transactions across multiple industries. Before joining Blackstone, Meng was a Senior Vice President at Oaktree Capital Management, where he was involved in sourcing, structuring and executing private equity investments in China. Prior to that, Mr. Gao was an investment banker with Credit Suisse and JPMorgan in New York.
Meng received a Bachelor of Economics degree from Peking University, an M.A. from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honours.
Norman joined NF Trinity Capital in 2017 and is currently an Associate focusing on early stage direct and fund investments in the life science sector. Before joining NFT, he was responsible for managing a global healthcare equity portfolio at family office of Global Sources (NASDAQ: GSOL), which was sold to Blackstone for US$480M in 2017. Prior to that, he was with Uni-Bio Science Group (HKSE: 0690) and closed multiple licensing deals with leading China and Korea pharmaceutical companies.
Norman earned a master degree in Bioengineering from UC Berkeley & UCSF and a bachelor degree in Biochemistry from the University of Hong Kong. He has completed the CFA program in 2017.
Jeni joined Nan Fung Life Sciences in 2019. She previously spent 3 years at Novo Ventures, supporting the firm’s investments in private and public life sciences companies across the therapeutics, medical device, diagnostics, and digital health sectors. While at Novo, she served as a Board Observer at Inozyme Pharma. Prior to Novo, Jeni supported the Director of Research at Aquilo Capital Management, a hedge fund focused on smid cap biotechs. Additionally, Jeni was a co-founder of ViVita Technologies, a cardiovascular-focused preclinical medtech startup. Jeni volunteers with the New England Venture Network (NEVN), a young professionals organization for aspiring venture capitalists, as well as the Breaking 7% network to promote women in venture capital.
Jeni earned her Ph.D. in Biomedical Engineering with a Designated Emphasis in Biotechnology from the University of California, Davis, and her B.S. from the University of California, Berkeley.